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Abstract
Staphylococcus aureus is an important cause of nosocomial and community-acquired infections in humans and
animals, as well as the cause of mastitis in dairy cattle. Vaccines aimed at preventing S. aureus infection in bovine
mastitis have been studied for many years, but have so far been unsuccessful due to the complexity of the
bacteria, and the lack of suitable vaccine delivery vehicles. The current study developed an Escherichia coli protein
expression system that produced a recombinant staphylococcal enterotoxin A (rSEA) encapsulated into
biodegradable microparticles generated by polylactic-co-glycolic acid (PLGA) dissolved in methylene chloride and
stabilized with polyvinyl acetate. Antigen loading and surface properties of the microparticles were investigated to
optimize particle preparation protocols. The prepared PLGA-rSEA microspheres had a diameter of approximately 5
μm with a smooth and regular surface. The immunogenicity of the PLGA-rSEA vaccine was assessed using mice as
an animal model and showed that the vaccine induced a strong humoral immune response and increased the
percent survival of challenged mice and bacterial clearance. Histological analysis showed moderate impairment
caused by the pathogen upon challenge afforded by immunization with PLGA-rSEA microspheres. Antibody titer in
the sera of mice immunized with PLGA-rSEA microparticles was higher than in vaccinated mice with rSEA. In
conclusion, the PLGA-rSEA microparticle vaccine developed here could potentially be used as a vaccine against
enterotoxigenic S. aureus.
Introduction
Staphylococcus aureus (S. aureus) is an important cause
of nosocomial and community-acquired infections in
humans and animals, and economic loss in animal hus-
bandry, such as mastitis in dairy cattle [1]. S. aureus can
provoke clinical mastitis but more frequently causes
subclinical infections that tend to become chronic and
difficult to eradicate by conventional antimicrobial
therapies [2,3].
The frequent incapacity of both the antibiotics and
immune response to prevent infection and destroy the
pathogen in the intramammary environment explains why
S. aureus bovine mastitis constitutes a major challenge to
dairy producers [4]. Multidrug-resistant S. aureus infec-
tions continue to increase, and some strains respond to
few, if any, conventional antibiotic therapies. Hence, inter-
est in immunotherapeutic strategies, either passive or
active, has seen resurgence in recent years. The pathogeni-
city of S. aureus results from structures that allow it to
avoid phagocytosis, the production of enzymes and toxins,
including exotoxins such as staphylococcal enterotoxins
(SE), toxic shock syndrome toxins (TSST), exoenzymes,
adhesins, and numerous cell-associated components that
either directly cause disease or facilitate tissue penetration
and immune cell recruitment [5,6]. Therefore, application
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phylactic measures against bovine mastitis.
Several studies have recently focused on S. aureus
toxins as vaccine targets [7-9]. SE, which are bacterial
superantigens (sAg) produced by S. aureus,p l a ya n
important role in establishing and maintaining infection
[5]. Immunization with recombinant or mutant staphylo-
coccal enterotoxin A (SEA) [10], staphylococcal entero-
toxin B (SEB) [11-13], and TSST-1 [12,14] can elicit
neutralizing antibodies against wild-type SE, and has
been shown to protect mice, rabbits, and monkeys
against lethal shock induced by wild-type superantigenic
toxins. Hu et al. have investigated a double-mutant sta-
phylococcal enterotoxin C (SEC) [15], that was devoid of
superantigenic activity, as an intranasal vaccine for pro-
tection against S. aureus challenge in mice. Other groups
recently studied a recombinant staphylococcal entero-
toxin C mutant in lactating dairy cattle and found that
vaccinated cattle had lower milk somatic cell counts and
lower numbers of intra-mammary infection than unvac-
cinated controls [16,17].
Modern vaccines based on subunits of pathogens,
such as purified proteins, are often unable to evoke
strong immune responses. One of the most important
challenges in the field is the selection of suitable adju-
vants and delivery systems. Suitable adjuvants must
enhance antigen specific immune responses, improve
protection through stimulation of optimal types of
immunity, and have low levels of adverse effects. Alum
is currently the only adjuvant approved for human use
by the United States Food and Drug Administration.
Although alum has an excellent safety record, compara-
tive studies showed that it is a poor adjuvant for recom-
binant proteins and DNA [18]. Additionally, alum is not
effective for eliciting IgA antibody responses and some
studies have even indicated that alum is associated with
allergic reactions in some subjects [19].
Biodegradable and biocompatible polyesters, such as
poly(lactic-co-glycolic acid) (PLGA), are one of the pri-
mary candidates for the development of microspheres as
vaccines, because they have been used in humans for
many years as suture material and as controlled-release
delivery systems for peptide drugs [20]. One of the most
attractive features of microspheres for vaccine develop-
ment is their ability to control the rate of release of
entrapped antigens over a longer period [21]. Ultimately,
this may allow the development of single-dose vaccines
through the preparation of microspheres that release
entrapped antigens at times when booster doses of vac-
cines would normally be administered. The development
of a single-dose vaccine would represent a significant
advance towards the preparation of an ideal vaccine that
would likely result in improved vaccine compliance, par-
ticularly for bovine mastitis.
T h ea i m so ft h i sp r e s e n ts t u d ya r e1 )t oe x p r e s sa n d
purify a recombinant SEA as a vaccine candidate and to
assess the efficiency of the PLGA adjuvant as a single-
dose delivery system; 2) to establish a mouse model to
investigate whether immunization with the PLGA-SEA
vaccine could protect against S. aureus infection.
Materials and methods
Mice
Six to eight-week-old female specific-pathogen-free (SPF)
mice were purchased from Merial-Vital Laboratory Ani-
mal Technology (Beijing, China). All animals were fed in
germ-free isolators and experiments were in compliance
with the guidelines of Beijing Municipality on the Review
of Welfare and Ethics of Laboratory Animals approved by
the Beijing Municipality Administration Office of Labora-
tory Animals.
Anesthesia
Sodium pentobarbital (50 mg/kg) was given i.p. prior to
all immunizations, collection of blood and bacterial chal-
lenge. A physical euthanasia method, cervical dislocation,
was performed for collection of tissues, as previously
described [22].
Bacterial strain and chemical agents
Enterotoxigenic S. aureus (ATCC13565) was purchased
from the Chinese National Center for Medical Type Cul-
ture Collections. The bacteria were cultured in tryptic
soy broth (TSB) at 37°C with agitation at 120 rpm.
Escherichia coli strains were grown in Luria-Bertani (LB)
broth or on LB agar plates in the presence or absence of
ampicillin (100 μg/mL).
Glutathione-S-transferase (GST)-fusion SEA protein
expression
For the amplification of the staphylococcal sea gene, pri-
mers (sea-1-774-F: 5’-CGGGATCCATGAAAAAAA-
CAGCATTTACA-3’; sea-1-774-R: 5’-CCGCTCGAG
TTAACTTGTATATAAATATATAT-3’; restriction
enzyme sites underlined) were designed according to the
published complete sea sequences (GenBank accession:
AJ33122). The bacterial DNA was extracted by EasyPure
Genomic DNAExtraction Kit (Transgen, Beijing, China).
The polymerase chain reaction (PCR) assay was per-
formed using 1 μL of DNA in a total reaction volume of
20 μLt h a tc o n t a i n e d1 0μL of Taq plus master mix
(Transgen), 10 pmol of each of the two primers, and
RNase-free H2O. The thermal cycling parameters used
were as follows: 5 min at 95°C, followed by 30 cycles of
60 s at 94°C, 60 s at 45°C, and 60 s at 72°C, followed by
extension for 10 min at 72°C. The reaction product was
visualized by agarose gel electrophoresis and further con-
firmed by nucleotide sequence analysis. The amplified
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pGEX-4 T-1 expression vector (GE Healthcare, Shanghai,
China). The recombinant expression vector, pGEX-sea,
was used to transform E. coli BL21 (DE3), and subse-
quently named pGEX-sea-BL21DE3.
The resultant recombinant E. coli strain was used to
express and purify a Glutathione S-transferase (GST)
fusion protein (designated rSEA) by affinity chromato-
graphy with Glutathione Sepharose 4 Fast Flow resin
(Henghuibio, Beijing, China) according to the manufac-
turer’s instructions. Protein concentration was deter-
mined by bicinchoninic acid (BCA) protein assay kit
(Solarbio, Beijing, China) and analyzed by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequent western immunoblot of GST
fusion protein visualized using an enhanced chemilumi-
nescence (ECL) Western Blot Kit (Beyotime Institute of
Biotechnology, Jiangsu, China), according to the manu-
facturer’s instructions. Mouse anti-GST tag monoclonal
antibody (M&C Gene Technology, Beijing, China) was
used as primary antibodies and horseradish peroxidase
(HRP)-conjugated rabbit anti-mouse IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA)
as secondary antibodies, as described previously [23].
Evaluation of the toxicity of recombinant SEA protein
To evaluate the toxicity and safety of the rSEA protein,
groups of BALB/c mice (5 mice per group) were intraperi-
toneally (i. p.) administered either 1 mg, 100 μgo r1 0μg
rSEA protein per mouse. Mice in the negative control
group were administered sterile phosphate-buffered saline
(PBS; pH 7.4). The positive control group was adminis-
tered i.p. 10 μg highly purified SEA (Sigma-Aldrich,
Shanghai, China). Mice were sacrificed 7 days after injec-
tion, and livers were removed and fixed with 10% neutral-
buffered formalin for histopathological evaluation, as
previously described [24].
Preparation and characterization of protein-loaded
microspheres
PLGA microspheres (MS) containing rSEA were pre-
pared by a water-in-oil-in-water (w/o/w) solvent extrac-
tion procedure, as previously reported [25]. Briefly,
100 mL of fusion protein (protein concentration, 5 mg/
mL) was added to 500 mg of PLGA (50:50; Daigan Biolo-
gical Materials, Shandong, China) in 10 mL of methylene
chloride. The mixture was emulsified by sonication at
output 300 W for 60 s to form the water-oil (w/o) emul-
sion. This emulsion was then added to 40 mL of 5%
aqueous polyvinyl alcohol (PVA, MW 31,000; Sigma-
Aldrich) solution to form the w/o/w emulsion. The
organic solvent was stirred at a moderate speed at ambi-
ent temperature for 10 h. The rSEA-loaded MS were cen-
trifuged at 5000 ×g for 45 min and then washed three
times with double-distilled water. The MS were then lyo-
philized and stored at -20°C. Core loading of rSEA in MS
was determined by digesting the MS and assaying the
protein concentration [26]. Briefly, 20 mg of MS was sus-
pended in 2 mL of 2.5% SDS/0.2 M NaOH solution, in
which the SDS ensures the complete solubilization of the
protein during polymer hydrolysis, and the resulting
solution was then neutralized by the stepwise addition of
1 M hydrochloric acid. The amount of surface-associated
protein was assessed by suspending the MS in PBS for 15
min, centrifuging the samples to sediment the MS, and
then analyzing the supernatant for protein using the
Bicinchoninic Acid (BCA) protein assay kit (Solarbio,
Beijing, China).
MS size and surface morphology were examined by
scanning electron microscopy (SEM; Hitachi S-3400;
Hitachi, Japan). The total protein release dynamics was
estimated using the BCA method [13,27,28]. Briefly,
100 mg of the MS were placed in test tubes containing 1
mL PBS (0.01 M; pH 7.4) and were incubated at 37°C
with rotation. At 10-day intervals, the samples were cen-
trifuged at 10 000 ×g for 10 min; the supernatant was col-
lected and assayed for protein release using the BCA
assay. The release study was continued after replacement
with the same volume of fresh buffer.
Immunization and determination of antibody responses
by enzyme-linked immunosorbent assay (ELISA)
Groups of six female BALB/c mice (6-8 weeks old) were
immunized i.p. with 100 μg of PLGA-rSEA, 100 μgo f
rSEA or 100 μg of empty PLGA. Control mice received
200 μL sterile PBS. Mice were restricted and were bled
from the caudal vein (about 50 μL once) on days 0, 7, 14,
21, 28, 35, and 42 post-immunization. Serum IgG against
SEA were assayed using an indirect ELISA [28]. Briefly,
96-well ELISA plates (Corning, Lowell, MA, USA) were
coated with 100 μL/well of a 0.5 μg/mL highly purified
SEA (Sigma-Aldrich) in carbonate buffer (0.01 M; pH
9.4) and incubated overnight at 4°C. The plates were
thoroughly washed three times with PBS containing
0.05% Tween-20 (PBS-T; pH 7.4) and treated with block-
ing buffer (5% skim milk in PBS-T) at 37°C for 2 h. After
washing, 100 μL of mouse serum (diluted 1:200 in PBS-
T) was added to each well and incubated at 37°C for 1 h.
After incubation, the plates were washed three times and
100 μL of HRP-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories) was added to each well.
The plates were incubated for 1 h at 37°C and washed
three times. To develop the plates, 100 μL/well tetra-
methylbenzidine substrate solution was added to each
well and incubated at 37°C for 15 min and stopped with
2MH 2SO4. The plates were read at 450 nm on an
ELISA reader (Thermo Fisher Scientific Inc., Shanghai,
China) and the results were reported as the OD450 of test
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control group) (P/N) [28].
Challenge studies
Six weeks after immunization as above, five mice from each
group were inoculated i.p. with S. aureus (ATCC13565) at
the lethal dosage of 2 × 10
9 colony forming units (CFU;
2L D 50). Infected mice were monitored daily for mortality
for 10 days.
Bacterial burden and histopathological analysis
Two groups of mice (12 mice per group), immunized
with either rSEA or PBS, were injected i.p. with sub-
lethal doses of S. aureus (10
8 CFU, 0.1 LD50) and sacri-
ficed 4 times on days 1, 3, 5, and 7 post-infection. Livers
and spleens were aseptically removed and homogenized
individually in 1 mL of sterile PBS. The viable bacterial
levels were enumerated by plating the serially diluted
homogenates on TSA medium. For histopathological eva-
luation, three immunized mice were sacrificed to excise
the liver, spleen, and kidney on day 9 after infection.
Organs were fixed in 10% neutral-buffered formalin and
processed using standard histological methods as above.
Statistical analysis
Data for the determination of bacterial burden and anti-
body level were expressed as mean ± standard error of the
mean, and all the test groups were compared to the con-
trol group using the Student’s t test. A P-value of < 0.05
was considered significant. Kaplan-Meier Log Rank meth-
ods were used for analyses of survival data. All statistics
were performed using the Origin software (version 8.0;
OriginLab, Northampton, MA, USA).
Results
Gene cloning and rSEA preparation
The sea gene isolated from S. aureus ATCC 13565 was
sequenced to ensure that there were no mutations intro-
duced during PCR amplification. SDS-PAGE showed that
the GST-SEA fusion protein had a relative molecular mass
of approximately 56 kDa expressed by the pGEX-sea-
BL21DE3 strain (Figure 1a). The expressed protein was
also demonstrated by western immunoblot (Figure 1b).
Toxicity evaluation
In order to ensure that the fusion SEA was safe when
administered as a vaccine, mice were injected i.p. with
different dosages of the recombinant protein. None of
the mice in the four groups showed any significant clini-
cal symptoms during the experiment period. However,
mice that received the high dose of rSEA (1 mg/mouse)
(Figure 1f) and low dose of highly purified SEA group
(10 μg/mouse) (Figure 1d) exhibited mild liver damage,
by histological examination. Focal necrosis of hepatocytes
and macrophage infiltration were obvious (Figure 1d, f).
No pathological change was observed in other groups
(Figure 1e). Therefore, the rSEA showed no significant
toxicity in the low dosage range (< 100 μg) in mice.
Characterization of PLGA microspheres
The PLGA entrapped rSEA MS exhibited a size range
from 1-5 μm in diameter with smooth surface under SEM
(Figure 2a). The protein loading level of the MS was calcu-
lated by the amount of rSEA in a given weight of the poly-
mer MS. The protein concentration in the MS was
determined by BCA assay and showed a 78% loading level
of the rSEA. The in vitro release kinetics of the rSEA was
evaluated via BCA assay (Figure 2b), showing that rSEA
was released over time. We found that rSEA had a sus-
tained release from the MS after 20 days and released
approximately 50% of loading dose in 50 days during poly-
mer hydrolysis.
Antibody response in mice
The SEA-specific antibody responses induced by PLGA
encapsulated rSEA were tested after i.p. administration.
For comparison, groups of mice were immunized with
non-adjuvanted rSEA and empty PLGA MS. Serum sam-
ples were collected at 7-day intervals. Antibodies devel-
oped against the SEA in serum were detected by indirect
ELISA. From the fourth week after immunization, the MS
vaccine induced significantly high antibody responses.
Antibody response of the PLGA-rSEA group was higher
than that of the rSEA group indicating that the MS adju-
vant enhanced the immunogenicity of rSEA (Figure 3).
Immuno-protection against bacterial infection
To determine whether the vaccine induced protection
against S. aureus infection, groups of mice were inocu-
lated with the MS entrapped with rSEA, or PBS, and then
challenged with appropriate doses of S. aureus.W h e n
challenged with a lethal dose of S. aureus, 80% (4/5) of
the unvaccinated mice died within 2 days post-infection
(Figure 4a). However, 100% of the mice vaccinated with
the microsphere vaccine survived.
It was next determined whether the increased survival in
rSEA immunized mice was due to control of bacterial
growth and dissemination during infection. Immunized-
and sham-control mice were challenged with 10
8 CFU/
mouse and bacterial burden in livers and spleens were
determined. Significant differences in CFU were observed
f r o md a y3p i( F i g u r e4 b ,c ) .N ob a c t e r i aw e r er e c o v e r e d
from spleens of all mice on day 7 (Figure 4c).
Histopathological analyses were performed with vacci-
nated and unvaccinated mice 9 days after challenge
(Figure 5). Vaccinated mice exhibited no obvious patho-
logical change in the liver, spleen, and kidney (Figure
5a, c, e). However, the livers of sham-vaccinated mice
Chen et al. Veterinary Research 2012, 43:20
http://www.veterinaryresearch.org/content/43/1/20
Page 4 of 11showed moderate infiltration of mononuclear cells
around the central veins (Figure 5b). In the spleen, lym-
phoid follicles were markedly decreased, and numerous
erythrocytes and macrophages appeared in the white
pulp (Figure 5d). Additionally, dilatation and hyperemia
was demonstrated in Bowman’s capsules of the kidney.
Necrotic and scaled tubular structure was also observed
(Figure 5f). These results show that using PLGA-SEA
could protect mice against S. aureus infection.
Discussion
S. aureus is a representative pathogen that can produce
a number of potential virulence factors, including hemo-
lysins, coagulase, leukocidin, enterotoxins, and TSST-1.
Figure 1 SEA expression and toxicity analysis. (A) SDS-PAGE for the rSEA induced by IPTG (1 mM) at different times; (B) Western immunoblot
for rSEA protein, using anti-GST as the capture antibody; (C) histological imaging of liver sections from mice injected with PBS, (D) from mice
injected with highly purified SEA protein, (E) low dose of rSEA experimental group, and (F) high dose of rSEA. Black arrows in D & F indicate the
focal necrosis of hepatocytes and macrophage infiltration.
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which is related to these factors to some extent, may
also vary among different strains of S. aureus [29]. It
has been postulated that persistent infection with S.
aureus is associated with an impaired immune response,
which is also mediated by factors produced by S. aureus.
Previous studies have investigated the role of S. aureus
exosecretions in bovine udders by intracisternally
Figure 2 Characteristics of the PLGA-rSEA. (A) Scanning electron microscopy (SEM) photograph of PLGA-rSEA. Microsphere size, morphology, and
surface appearance were examined by SEM. (B) Antigen-release kinetics. Percentage of released antigen was detected by BCA assay from day 10- 50.
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from various strains of S. aureus [30,31].
SE have many distinct biological activities and can
escape from normal host adaptive immune responses.
For example, SE have the ability to bind to the major his-
tocompatibility class II (MHC-II) molecules and specific
V-segments of T-cell receptors (TCR) outside the bind-
ing groove that are associated with MHC-restricted
immune system recognition of processed peptides. The
binding of SAg to MHC-II and TCR stimulates abnor-
mally large numbers of T cells. SE exert various deleter-
ious effects, including induction of shock, cytokine
induction, T-cell unresponsiveness and clonal deletion,
differential stimulation of CD4
+ and CD8
+ T-cell subsets,
and B-cell differentiation [30-32]. Although largely
unconfirmed, in cases of bovine mastitis, there is a clear
potential for SE to modulate immune responses and con-
tribute to the virulence and persistence of S. aureus in
cattle [17].
SE are believed to be related to common biological
activities of toxins, which include pyrogenicity, immune
response suppression, cytokine induction, proliferation of
lymphocytes, and superantigenicity. Such biological activ-
ity plays an important role in lethal diseases, such as
toxic shock syndrome. If the amino acid sequence of
these functional structures is deleted or substituted with
another amino acid sequence, SE can be used as vaccines
or therapies in humans or animals. Bavari et al. [10]
demonstrated that rSEA refers to SEA that has been
mutated in the class II binding site and was safely used as
a vaccine, which was also proved in a study performed by
Collins et al. [33].
The N- and C-terminal peptides of SEA are important
sites for interaction with MHC-II molecule or TCR. In
the current study, the production of a recombinant
expression vector containing the sea gene linked with the
GST gene at the 5’-end suggests that the rSEA is altered
leading to the loss of MHC-II and TCR binding sites.
The reduction in toxicity compared to the native protein
in this study suggests that it has reduced superantigenic
activity, but further experiments are required to confirm
that this is the case. Admittedly, further studies on rSEA
toxicity through other aspects and in other animals, such
as cattle and humans, should be performed for practical
use of the rSEA based vaccines.
The use of polymeric MS as vaccine adjuvants and deliv-
ery systems has been investigated for their many advan-
tages [34,35]. It has been demonstrated that a stronger
immune response is elicited when an antigen is associated
with MS compared with a soluble antigen alone. The
delivery system controls the release of the entrapped anti-
gens slowly and continuously. The most significant feature
of a PLGA vaccine is the one-dose administration [36,37],
and this was confirmed in the current study. The effect of
particle size on immunogenicity is likely to be a conse-
quence of enhanced uptake into the lymphatics and
greater uptake into antigen-presenting cells for the smaller
sized particles, since only MS < 5 μmw e r ep r o v e nt ob e
Figure 3 Serum antibody analysis. Antibody levels in mice serum. Sera were collected from vaccinated and unvaccinated controls as
described in the text. The error bars indicate standard errors of the means for five mice per group. The asterisks indicate P values (*, P < 0.05; **,
P < 0.01, compared with the PBS group).
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Page 7 of 11Figure 4 In vivo evaluation of the PLGA-rSEA vaccine protection. (A) Percent survival after infection; (B) In vivo growth of S. aureus in the
liver after challenge; (C) In vivo growth of S. aureus in the spleen after challenge. BALB/c mice were vaccinated with PLGA-rSEA and then
challenged i.p. with 10
8 CFU of S. aureus for bacterial clearance analysis (A and B) and 10
9 CFU lethal doses of S. aureus for percent survival
analysis (C) (*, P < 0.05; **, P < 0.01, compared with the PBS group).
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polymer is dependent on the actual needs of the antigen
delivery system. The erosion of the polymer is dependent
on two main parameters, molecular weight and monomer
ratios; the higher the molecular weight of the polymer, the
longer the time it will need to erode in vivo, and therefore
will have a slower release. Also, the monomer ratios of lac-
tic acid and glycolic acid in the polymer backbone affect
erosion. Higher lactic acid content slows erosion rates in
comparison to higher glycolic acid content. In the current
study, polymers with molecular weight of 100 kDa, which
is ideal for a two-month delivery time, were used to form
the MS. This is consistent with other published work
[20,27].
To prepare antigen entrapped MS, a certain amount of
polymer is required to be present to ensure complete
entrapment of the antigen within the particle. A 4-6%
polymer solution is ideal for making small MS (< 10 μm)
[25]; thus, we used a 5% polymer solution to prepare the
MS. As observed by SEM (Figure 2a), the particle size of
MS were between 1-5 μm.
Currently, vaccine efficacy against S. aureus is defined
as an increase in the spontaneous cure rate [39-42]. In
our study, antibody experiments showed a significantly
Figure 5 Histological analysis of mice after challenge with S. aureus. (A) Liver histopathology from mice challenged with S. aureus after
vaccination with PLGA-rSEA. (B) Liver histopathology of unvaccinated mice challenged with S. aureus. The black arrow indicates moderate
infiltration of mononuclear cells around the central veins (C) Spleen histopathology of mice immunized with PLGA-rSEA. (D) Spleen
histopathology of unvaccinated mice. (E) Kidney histopathology of mice immunized with PLGA-rSEA. The black arrow indicates erythrocytes and
macrophages in the white pulp. (F) Kidney histopathology of unvaccinated mice. BALB/c mice were vaccinated and then challenged i.p. with 10
8
CFU of S. aureus six weeks after immunization. Mice were sacrificed on day 9 after challenge for this analysis. Tissues were stained with
hematoxylin and eosin. Black arrows indicate the necrotic and scaled of the tubular structure.
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aureus. Lethal-dose experiments demonstrated that the
PLGA-rSEA vaccine increased percent survival at a high
dose (10
9 CFU/mouse) of S. aureus and histological
tests proved that this vaccine caused less pathological
damage at a lower dose (10
8 CFU/mouse) of this entero-
toxigenic strain. Further, the PLGA adjuvant stimulated
the host humoral immune response (Figure 5). However,
no significantly increased differentiation of either CD4
+
or CD8
+ cells after vaccination were observed in our
study according to flow cytometric assays (data not
shown), although some published work proved that the
cell-mediated immune response could be enhanced by
PLGA adjuvant [43-46]. Therefore, further investigation
is necessary to fully understand how the PLGA particles
interact with the cell-mediated immune system. Due to
the protective efficiency of the PLGA-rSEA MS vaccine
developed in this study, we suggest that it should be pos-
sible to develop a subunit vaccination approach asso-
ciated with PLGA MS for effective antibody-mediated
protection against S. aureus. However, given the nature
of S. aureus and the lessons learned from the recent fail-
ure of some emerging vaccines in phase III trials [47], it
is clear that a multi-component vaccine is essential.
Studies presented here indicate a positive approach to
developing an efficient multi-component bovine mastitis
vaccine that may contain different enterotoxins and other
binding proteins associated with the high performance
adjuvant, PLGA. This vaccine will be a promising strat-
egy for preventing S. aureus caused bovine mastitis,
because single dose administration presents significant
superiority in treating dairy cows.
In conclusion, our strategy to combine rSEA with 5%
PLGA polymer solution making 5 μm microspheres as a
vaccine with a one-dose administration for two-month
delivery proved to be a good inducer of immune responses
against S. aureus infection in the mouse model. It pro-
duced high anti-SEA antibody titer and percent survival,
as well as less pathological damage. These preliminary
data are encouraging and underline the feasibility of a pro-
tective vaccine.
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